Abstract
Purpose
Small interfering RNAs (siRNAs) specifically and potently inhibit target gene expression. Pachyonychia congenita (PC) is a skin disorder caused by mutations in genes encoding keratin (K) 6a/b, K16, and K17, resulting in faulty intermediate filaments. A siRNA targeting a single nucleotide, PC-relevant mutation inhibits K6a expression and has been evaluated in the clinic with encouraging results.
Procedures
To better understand the pathophysiology of PC, and develop a model system to study siRNA delivery and visualize efficacy in skin, wild type (WT) and mutant K6a complementary DNAs (cDNAs) were fused to either enhanced green fluorescent protein or tandem tomato fluorescent protein cDNA to allow covisualization of mutant and WT K6a expression in mouse footpad skin using a dual fluorescence in vivo confocal imaging system equipped with 488 and 532 nm lasers.
Results
Expression of mutant K6a/reporter resulted in visualization of keratin aggregates, while expression of WT K6a/reporter led to incorporation into filaments. Addition of mutant K6a-specific siRNA resulted in inhibition of mutant, but not WT, K6a/reporter expression.
Conclusions
Intravital imaging offers subcellular resolution for tracking functional activity of siRNA in real time and enables detailed analyses of therapeutic effects in individual mice to facilitate development of nucleic acid-based therapeutics for skin disorders.
Similar content being viewed by others
References
Zhou Y, Zhang C, Liang W (2014) Development of RNAi technology for targeted therapy—a track of siRNA based agents to RNAi therapeutics. J Control Release 193:270–281
Haussecker D (2014) Current issues of RNAi therapeutics delivery and development. J control Release : Off J Control Release Soc 195:49–54
Kubowicz P, Zelaszczyk D, Pekala E (2013) RNAi in clinical studies. Curr Med Chem 20:1801–1816
Leachman SA, Hickerson RP, Schwartz ME et al (2010) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 18:442–446
Leachman SA, Hickerson RP, Hull PR et al (2008) Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51:151–157
Gonzalez-Gonzalez E, Kim YC, Speaker TJ et al (2011) Visualization of plasmid delivery to keratinocytes in mouse and human epidermis. Sci Rep 1:158
Leachman SA, Kaspar RL, Fleckman P et al (2005) Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 10:3–17
McLean WH, Hansen CD, Eliason MJ, Smith FJ (2011) The phenotypic and molecular genetic features of pachyonychia congenita. J Investig Dermatol 131:1015–1017
Smith FJD, Hansen CD, Hull PR et al (2014) Pachyonychia congenita. GeneReviews:http://www.ncbi.nlm.nih.gov/books/NBK1280/
Cao YA, Hickerson RP, Seegmiller BL et al (2015) Gene expression profiling in pachyonychia congenita skin. J Dermatol Sci 77:156–165
Hickerson RP, Smith FJ, Reeves RE et al (2008) Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Investig Dermatol 128:594–605
Hickerson RP, Leachman SA, Pho LN et al (2011) Development of quantitative molecular clinical end points for siRNA clinical trials. J Investig Dermatol 131:1029–1036
Ra H, Piyawattanametha W, Gonzalez-Gonzalez E et al (2011) In vivo imaging of human and mouse skin with a handheld dual-axis confocal fluorescence microscope. J Investig Dermatol 131:1061–1066
Hickerson RP, Gonzalez-Gonzalez E, Vlassov AV et al (2012) Intravital fluorescence imaging of small interfering RNA-mediated gene repression in a dual reporter melanoma xenograft model. Nucl Acid Ther 22:438–443
Diaconeasa A, Boda D, Neagu M et al (2011) The role of confocal microscopy in the dermato-oncology practice. J Med Life 4:63–74
Calzavara-Pinton P, Longo C, Venturini M, Sala R, Pellacani G (2008) Reflectance confocal microscopy for in vivo skin imaging. Photochem Photobiol 84:1421–1430
Hickerson RP, Vlassov AV, Wang Q et al (2008) Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 18:345–354
Lara MF, Gonzalez-Gonzalez E, Speaker TJ et al (2012) Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. Hum Gene Ther 23:816–823
Smith FJ, Hickerson RP, Sayers JM et al (2008) Development of therapeutic siRNAs for pachyonychia congenita. J Investig Dermatol 128:50–58
Wang Q, Ilves H, Chu P et al (2007) Delivery and inhibition of reporter genes by small interfering RNAs in a mouse skin model. J Investig Dermatol 127:2577–2584
Gonzalez-Gonzalez E, Ra H, Hickerson RP et al (2009) siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. Gene Ther 16:963–972
Hickerson RP, Wey WC, Rimm DL et al (2013) Gene silencing in skin after deposition of self-delivery siRNA with a motorized microneedle array device. Mol Ther Nucl Acids 2, e129
Schwarz DS, Ding H, Kennington L et al (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2, e140
Allen EH, Atkinson SD, Liao H et al (2013) Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy. Invest Ophthalmol Vis Sci 54:494–502
Ohnishi Y, Tamura Y, Yoshida M, Tokunaga K, Hohjoh H (2008) Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLoS One 3, e2248
Leslie Pedrioli DM, Fu DJ, Gonzalez-Gonzalez E et al (2012) Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder. J Investig Dermatol 132:1627–1635
Hegde V, Hickerson RP, Nainamalai S et al (2014) In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation. J Control Release 196:355–362
Gonzalez-Gonzalez E, Speaker TJ, Hickerson RP et al (2010) Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD). Mol Ther 18:1667–1674
Steinstraesser L, Lam MC, Jacobsen F et al (2014) Skin electroporation of a plasmid encoding hCAP-18/LL-37 host defense peptide promotes wound healing. Mol Ther 22:734–742
Zheng D, Giljohann DA, Chen DL et al (2012) Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci 109:11975–11980
Chen M, Zakrewsky M, Gupta V et al (2014) Topical delivery of siRNA into skin using SPACE-peptide carriers. J Control Release 179:33–41
Cheng J, Syder AJ, Yu QC et al (1992) The genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes. Cell 70:811–819
Irvine AD, McLean WH (1999) Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br J Dermatol 140:815–828
Acknowledgments
The authors would like to thank Conor Cox for his efforts in acquiring the confocal microscopy and fluorescent histological data. We also thank Robert Kaspar, Heini Ilves, and Jed Humphries for technical support and Andrea Burgon for administrative support. This work was supported by NIH grants R44AR056559 (RLK, CHC) and the Chambers Family Foundation (CHC).
Conflict of Interest
Roger Kaspar and Robyn Hickerson have patents issued and pending on using siRNA to treat PC and siRNA delivery technologies.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Supplementary Video 1
(Movie showing full dataset from Fig. 3.) Separate intradermal injections of distinct reporter expression plasmids to mouse footpads results in distinct subsets of keratinocytes that express each reporter protein. To determine if successive intradermal injections would result in delivery and expression of reporter genes in the same, or different, subsets of cells, two separate injections (12 h apart) of plasmids expressing differentially-labeled reporter proteins were performed. The expression construct pUBC-K6a(N171K)-tdTFP was injected into a mouse footpad at time 0. At 12 h, pUBC-K6a(WT)-EFGP was injected into the same footpad, as close to the original injection site as possible. The footpad skin was imaged at 36 h using the intravital scope. a Reflectance was used to visualize skin structure and create a reference image. Fluorescence using b 488 and c 532 nm lasers are d overlaid to show the subsets of cells expressing the reporter protein from each injection. (AVI 10221 kb)
Supplementary Video 2
As described in Fig. 4, mouse paws were imaged with the confocal imaging VivaScope. Movie shows all images collected every 2 μm from the skin surface to a depth of 130 μm. En face images using reflectance and green and red fluorescence from both paws are shown. Note that the left panel in (c) is reflectance microscopy to show general skin structure. (AVI 32240 kb)
Supplementary Video 3
(Movie showing full dataset from Fig. 5.) Intravital visualization of mutant and wildtype K6a expression in skin. The expression plasmids pUBC-K6a(WT)-EGFP (pTD239, a) or pUBC-K6a(N171K)-EGFP (pTD240, b) were intradermally injected (40 μg in 70 μL PBS) into mouse footpads and imaged (24 h). a WT K6a expression is generally uniformly expressed throughout the cytoplasm of each cell leaving a dark nuclear region in the center of each cell (arrows depict examples). b Mutant N171K K6a/EGFP expression results in pronounced (as compared to WT expression) aggregation. (AVI 3714 kb)
Rights and permissions
About this article
Cite this article
Hickerson, R.P., Speaker, T.J., Lara, M.F. et al. Non-Invasive Intravital Imaging of siRNA-Mediated Mutant Keratin Gene Repression in Skin. Mol Imaging Biol 18, 34–42 (2016). https://doi.org/10.1007/s11307-015-0875-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-015-0875-z